Amgen posts Q3 2026 earnings beat and lifts full‑year revenue and profit guidance
Amgen reported third‑quarter 2026 revenue of $10.4 billion, up 8% year‑over‑year, and GAAP EPS of $7.08, a 19% increase. Adjusted (non‑GAAP) EPS rose 14% to $6.45, beating analyst estimates. The company raised its full‑year 2026 revenue outlook to $38.9‑$39.7 billion and non‑GAAP EPS outlook to $22.90‑$23.70 per share. Shares slipped in after‑hours trading as investors noted biosimilar competition hitting Prolia and XGEVA sales.
Why it matters
The higher guidance expands the revenue target by up to $1.8 billion and lifts profit expectations, which could improve future cash flow and dividend capacity (the company announced a 6% dividend increase). However, the post‑earnings share decline reflects market concern over biosimilar pressure on key bone‑health products, which may temper short‑term price performance.
Key facts
- 1Total Q3 2026 revenues increased 8% to $10.4 billion versus Q3 2025. prnewswire.com
- 2GAAP earnings per share rose 19% from $5.93 to $7.08 for the quarter. prnewswire.com
- 3Non‑GAAP earnings per share increased 14% from $5.64 to $6.45. prnewswire.com
- 4Free cash flow for the quarter was $3.7 billion, down from $4.2 billion a year earlier. prnewswire.com
- 5Full‑year 2026 revenue guidance was raised to $38.9‑$39.7 billion. finance.yahoo.com
- 6Full‑year 2026 non‑GAAP EPS guidance was raised to $22.90‑$23.70 per share. seekingalpha.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.